Literature DB >> 6841002

Corneal re-epithelialization in galactosemic rats.

M B Datiles, P F Kador, H N Fukui, T S Hu, J H Kinoshita.   

Abstract

Abnormalities in corneal epithelial healing in diabetic patients have been described recently. Defects in corneal re-epithelialization in diabetic rats have been reported, and it was found that treatment with aldose reductase (AR) inhibitors effectively prevented these defects. Experiments using galactosemic rats to study further the role of AR in these defects, since AR is known to be the common factor involved in sugar cataractogeneses, are reported herein. Similar defects in corneal re-epithelialization in galactosemic rats as in diabetic rats were found. The delay in re-epithelialization was documented by computer planimetry. Light microscopy showed marked corneal stroma edema and wider intercellular spaces in the epithelium after complete re-epithelialization, while scanning electron microscopy revealed fewer filopodia projecting from the leading margin during the active migration stage. These defects were prevented by treating galactosemic rats with the aldose reductase inhibitor, Pfizer's Sorbinil. These suggest that AR plays a role in the defects in corneal re-epithelialization observed in diabetes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6841002

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

Review 1.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

Review 2.  Diabetic complications in the cornea.

Authors:  Alexander V Ljubimov
Journal:  Vision Res       Date:  2017-04-28       Impact factor: 1.886

3.  Kinematics of epithelial wound closure in the rabbit cornea.

Authors:  L S Kwok
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

Review 4.  Sorbitol, osmoregulation, and the complications of diabetes.

Authors:  M B Burg; P F Kador
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

Review 5.  Ocular complications of diabetes mellitus.

Authors:  Nihat Sayin; Necip Kara; Gökhan Pekel
Journal:  World J Diabetes       Date:  2015-02-15

6.  Impaired epithelial wound healing and EGFR signaling pathways in the corneas of diabetic rats.

Authors:  Keping Xu; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-17       Impact factor: 4.799

7.  Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.

Authors:  H Fujishima; K Tsubota
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

Review 8.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Matthew S Klocek; Ian S Zagon
Journal:  Brain Res Bull       Date:  2009-08-14       Impact factor: 4.077

9.  LL-37 via EGFR transactivation to promote high glucose-attenuated epithelial wound healing in organ-cultured corneas.

Authors:  Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-24       Impact factor: 4.799

10.  Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Cheruku S Rao; Jonathan L Vennerstrom; Jack DeRuiter; Uday B Kompella
Journal:  J Pharm Pharmacol       Date:  2004-03       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.